Kamyar Kalantar-Zadeh M.D. to Acute Coronary Syndrome
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Acute Coronary Syndrome.
Connection Strength
0.864
-
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovasc Diabetol. 2021 06 22; 20(1):125.
Score: 0.182
-
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021 05 08; 16(5):705-716.
Score: 0.180
-
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021 01 07; 20(1):13.
Score: 0.176
-
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020 04 28; 323(16):1565-1573.
Score: 0.168
-
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
Score: 0.159